I have two promising novel classes of anticancer drugs with first in class attributes available for in licensing.

The Non Proteolytic Proteasome Inhibitor demonstrated a Proteasome inhibition through a novel mechanism/target. This compound is currently at the lead generation stage.

POC : In-vitro cytotoxicactivity on human cancer cells

A screening platform could be discussed as well

Please contact

Jean-Charles Brosse

e-mail :

This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

mobile : +33607832134 

Comments

Add New Search RSS

SEO Class   |2012-06-07 01:41:21 But everyone says they have promising new drugs. I hope yours is the exception that shows the world that cancer can be completely overcome! Reply

Write comment
Name:
Email:	do not notifynotify
Website:
Title:
	Please input the anti-spam code that you can read in the image.

Powered by !JoomlaComment 3.26

3.26 Copyright (C) 2008 Compojoom.com / Copyright (C) 2007 Alain Georgette / Copyright (C) 2006 Frantisek Hliva. All rights reserved."

• New Joint Health Supplement (15/01/2013)
• Novel Herbal Product for White Discharge in Women (01/09/2012)
• NCE for oncology - Improved HDAC inhibitors (12/02/2012)

• Treatment of gastrointestinal disorders using kynureic acid (29/04/2010)
• A natural preparation for the relief of anxiety (29/04/2010)
• Victory Pharmaceuticals - Late Stage Development Program in Pain Management (15/12/2009)
• Co- development offer for innovatve topical for Psoriasis (29/10/2009)
• Variant of Tumor Necrosis Factor (TNF)-? : Anti-tumor agent acting on Melanoma & Soft Tissue Sarcoma (13/10/2009)
• Antituberculosis - synergistic formulation (15/04/2009)
• Innovative Compound Extracted from Citrus (23/03/2009)
• NO-donating molecule (17/06/2008)
• The Death Gene (24/02/2008)